RMAT– tag –
-
Cellectis’ Lasme-cel Receives FDA RMAT Designation as First Allogeneic CAR T in Pivotal Trial for R/R B-ALL, EHA Data Confirms Efficacy
Stock Titan (Cellectis SEC Filing) USA Overview Cellectis announced that its CD22-targeting allogeneic CAR T-cell therapy candidate, lasme-cel (UCART22), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ...
